OSR (NASDAQ:OSRH) and Madrigal Pharmaceuticals (NASDAQ:MDGL) Head-To-Head Review

Madrigal Pharmaceuticals (NASDAQ:MDGL) and OSR (NASDAQ:OSRH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Valuation and Earnings

This table compares Madrigal Pharmaceuticals and OSR”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.28 billion	7.74	-$288.28 million	($12.89)	-33.39
OSR	$1.81 million	2.72	-$27.06 million	($0.37)	-0.38

OSR has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Madrigal Pharmaceuticals and OSR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	2	15	0	2.78
OSR	1	0	0	0	1.00

Madrigal Pharmaceuticals presently has a consensus target price of $699.20, suggesting a potential upside of 62.47%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Madrigal Pharmaceuticals is more favorable than OSR.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, OSR has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Insider & Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Madrigal Pharmaceuticals and OSR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
OSR	-593.15%	-8.36%	-6.24%

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.